Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Oncology Drugs Available In U.S. But Australians Pay 30% Less - Tufts Study

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Oncology drug prices in Australia were roughly 30 percent lower than in the U.S. over the past decade, thanks to comparative effectiveness policies imposed by Australia's Pharmaceutical Benefits Scheme, according to a recent study conducted by the Tufts Center for the Study of Drug Development

You may also be interested in...



Pricing And Commercial Strategies For Emerging Markets Need To Be Built Into Drug Development Programs Early - DIA Conference

CHICAGO - Emerging markets represent a plethora of opportunity for multinational pharma companies, but they also represent a confusing mix of pricing and reimbursement policies that change rapidly and are not always clear

Pricing And Commercial Strategies For Emerging Markets Need To Be Built Into Drug Development Programs Early - DIA Conference

CHICAGO - Emerging markets represent a plethora of opportunity for multinational pharma companies, but they also represent a confusing mix of pricing and reimbursement policies that change rapidly and are not always clear

Aussie Health Chief Vows To End Delay In Doctor PBS Prescriptions

Australia's health minister says the government is taking steps to ease some of the delays in physician ability to prescribe covered drugs

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel